A new trading day began on Tuesday, with Myriad Genetics, Inc (NASDAQ: MYGN) stock price down -2.76% from the previous day of trading, before settling in for the closing price of $3.98. MYGN’s price has ranged from $3.76 to $29.30 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -105.58%. With a float of $87.40 million, this company’s outstanding shares have now reached $92.20 million.
The firm has a total of 2700 workers. Let’s measure their productivity. In terms of profitability, gross margin is 70.01%, operating margin of -14.98%, and the pretax margin is -15.27%.
Myriad Genetics, Inc (MYGN) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Myriad Genetics, Inc is 5.19%, while institutional ownership is 103.08%. The most recent insider transaction that took place on Oct 11 ’24, was worth 343,950. In this transaction President and CEO of this company sold 15,000 shares at a rate of $22.93, taking the stock ownership to the 962,378 shares. Before that another transaction happened on Oct 11 ’24, when Company’s Officer proposed sale 15,000 for $22.93, making the entire transaction worth $343,950.
Myriad Genetics, Inc (MYGN) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -105.58% per share during the next fiscal year.
Myriad Genetics, Inc (NASDAQ: MYGN) Trading Performance Indicators
Here are Myriad Genetics, Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.12, a number that is poised to hit 0.01 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Myriad Genetics, Inc (MYGN)
Analysing the last 5-days average volume posted by the [Myriad Genetics, Inc, MYGN], we can find that recorded value of 1.86 million was better than the volume posted last year of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 15.12%.
During the past 100 days, Myriad Genetics, Inc’s (MYGN) raw stochastic average was set at 1.64%, which indicates a significant decrease from 8.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.24 in the past 14 days, which was lower than the 0.37 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.84, while its 200-day Moving Average is $10.54.
